PLERIXAFOR EUGIA
As listed in the register: PLERIXAFOR EUGIA 20 MG/ML SOLUCIÓN INYECTABLE EFG
20 mg/ml · solución inyectable
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Plerixafor
- Made by
- Eugia Pharma (Malta) Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Plerixafor). It describes the substance, not this exact product.
Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α).
SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment.
Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5).
Following a 0.24 mg/kg dose in healthy volunteers with normal renal function, approximately 70% of the dose was excreted in the urine as the parent drug during the first 24 hours following administration.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-06
Safety of the active substance
From the US prescribing label for the same active substance (Plerixafor). It describes the substance, not this exact product.
- Plerixafor is contraindicated in patients with a history of hypersensitivity to plerixafor [see Warnings and Precautions (5.1)].
- Anaphylactic shock has occurred with use of plerixafor.
- History of hypersensitivity to plerixafor.
The most common adverse reactions (≥10%) reported in patients who received plerixafor in conjunction with filgrastim regardless of causality and more frequent with plerixafor than placebo during HSC mobilization and apheresis were diarrhea, nausea, fatigue, injection site reactions, headache, arthralgia, dizziness, and vomiting.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States1 matching products
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands6 matching products
- Mozobil 20 mg/ml 20 mg/ml · oplossing voor injectie
- Plerixafor Accord 20 mg/ml oplossing voor injectie 20 mg/ml · oplossing voor injectie
- Plerixafor Amarox 20 mg/ml oplossing voor injectie 20 mg/ml · oplossing voor injectie
- Plerixafor Seacross 20 mg/ml oplossing voor injectie 20 mg/ml · oplossing voor injectie
- Plerixafor Teva 20 mg/ml 20 mg/ml · oplossing voor injectie
- Plerixafor Vivanta 20 mg/ml 20 mg/ml · oplossing voor injectie
SwitzerlandNo exact match for this strength and form
Details
| Made by | Eugia Pharma (Malta) Limited |
|---|---|
| Active substance | Plerixafor |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg/ml |
| Form | solución inyectable |
| Classification | L03AX16 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | Yes, according to the register |
| Generic | Yes — a generic medicine, according to the register |
| Name in the register | PLERIXAFOR EUGIA 20 MG/ML SOLUCIÓN INYECTABLE EFG |
| Nº Registro | 88723 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.